{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972359",
  "id": "02972359",
  "pages": 3,
  "price_sensitive": false,
  "date": "20250724",
  "time": "1332",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250724/pdf/06m3d750x001ct.pdf",
  "summary": "### Key Material Information:  \n- **Clinical Validation**: Next-gen PromarkerD test achieves:  \n  - **AUC 0.88** (excellent discrimination) and **97.4% negative predictive value** in predicting diabetic kidney disease (DKD).  \n  - **44-fold greater odds** of kidney decline in high-risk vs. low-risk patients.  \n  - Identifies **86% of at-risk patients missed by standard tests**.  \n- **Commercial Readiness**: Test now available in **Australia and USA** for Type-2 diabetes patients.  \n- **Market Potential**: Addresses **537 million adults globally** at risk of DKD, enabling earlier intervention and cost savings.  \n\n*No capital raising, financials, or trading-related information disclosed.*",
  "usage": {
    "prompt_tokens": 2550,
    "completion_tokens": 158,
    "total_tokens": 2708,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T04:12:01.378782"
}